Shares of Seattle based CTI Biopharma (NASDAQ: CTIC) have rallied premarket after it was announced yesterday evening that the company will submit a New Drug Application (NDA) to the FDA for the approval of its drug pacritnib.
The drug is used as a treatment for myelofibrosis patients with severe thrombocytopenia.
CTI said that the NDA will be based on data from its completed Phase 2 (PERSIST-1 and PERSIST-2) and Phase 3 (PAC203) trials. In contrast, its ongoing Phase 3 PACIFICA trial is expected to be completed as a post-marketing commitment.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
The FDA has agreed to a rolling NDA submission, which will commence soon and is expected to be completed in Q1 2021.
CTI’s President and Chief Executive, Adam R. Craig, MD, PHD, said “There is no approved drug that specifically addresses the unmet need of the myelofibrosis patients who have severe thrombocytopenia.
“Pacritinib has demonstrated clinical benefit in treating these patients in multiple trials and now has the potential to become a new treatment option for treatment-naïve and second-line myelofibrosis patients in 2021.”
The news has seen CTI’s stock price mount a strong rally premarket. After yesterdays close at $1.05, it is now up 176.19% at $2.90 per share, a level not traded at since July 2018.
For the year to date, CTI shares are down 33%.
PEOPLE WHO READ THIS ALSO VIEWED:
